Latest Articles
Article
Addressing Gender Bias – “It Is Time to End the Tradition in Science of All-Male Speaking Panels”
Francis S. Collins, M.D., Ph.D. Director of the National Institutes of Health, has recently directly addressed the issue of underrepresented groups in science: "Too often, women and members of other groups underrepresented in science are conspicuously missing in the marquee speaking slots at scientific meetings and other high-level conferences.”
Article
The Evolution of Proteomics - Professor John Yates
The final instalment of The Evolution of Proteomics series features an interview with Professor John Yates from the Department of Molecular Medicine at Scripps Research. The Yates laboratory is focused on developing strategies and tools in proteomics to answer basic biological questions.
Article
An Interview With CRISPR Pioneer Jennifer A. Doudna
In this interview, award-winning scientist Jennifer A. Doudna PhD – renowned for her fundamental work and leadership in developing CRISPR-mediated genome editing – touches on her current research focus, her greatest professional achievements and discusses what can be done to encourage more women to get involved in science.
Article
Next-Generation Sequencing (NGS): Stimulating the Next Generation of Cancer Diagnostics and Treatment
The "molecular age" of cancer research is here, thanks to advances in next generation sequencing (NGS) which have catalyzed progress in countless areas of cancer research. Find out about the latest studies where NGS is improving our ability to detect cancer, match the best drugs to patients, and monitor treatment success.
Article
Cell Migration: Clinical Relevance, Unique Movement Patterns and Driving Technologies
Cells like to move it, move it! Understanding the mechanisms behind cell migration represents an important piece to the puzzle of many fundamental biological processes and pathologies. This article delves into textbook models of cell migration, recent insights on movement patterns, and highlights the technology driving cell migration research forward.
Article
The Evolution of Proteomics - Professor Emanuel Petricoin
This week's instalment of "The Evolution of Proteomics" features an interview with Emanuel Petricoin. Dedicating his career to driving the clinical proteomics field forward, Petricoin's research focuses on the development of cutting-edge microproteomic technologies, identifying and discovering biomarkers for early disease detection and creating nanotechnology tools for analyte detection, drug delivery and monitoring.
Article
W的代码ild: A Documentary Film Exploring the Genome Editing Revolution
In the Code of the Wild documentary film, Cody Sheehy (award winning producer and director) and CRISPR scientist Samira Kiani explore the controversial and secretive world of genetic engineering. In an interview with Kiani and Sheehy, we cover all aspects of Code of the Wild, including the making of the documentary film, the discovery of Jiankui He's experiment that shook the world and the concept of being able to "purchase" a longer life span.
Article
The First Winners of the LEA
The Lipidomics Excellence Award (LEA) was founded to strengthen life sciences through lipidomics. After reviewing the many high-quality submitted projects, the LEA jury has announced the three awardees.
Article
Whole-Exome Sequencing at the Dawn of Personalized Medicine
Deciphering the first complete sequence of the human genome in 2003 required a combined effort of scientists from 20 institutions and $3 billion of funding. Over the last decade, whole-exome sequencing (WES) established itself as a method that successfully balances cost and the output of useful data for diagnostic or research applications. Here, we look at how WES is used in both the laboratory and the clinic, and why it is a preferred method of choice in such areas.
Article
Antibodies in Research: The Good, the Bad, and the Validation Epidemic
The specificity of antibody binding is incredibly important for many research disciplines, yet sourcing the best antibody for your research can be a challenge. This is partly because not all suppliers validate their antibodies sufficiently. How much of a problem is this?
Advertisement